natgillin/translations-raw huggingface dataset:
As metformin is excreted by the kidney, serum creatinine concentrations should be determined regularly:
Zaradi izločanja metformina skozi ledvice je potrebno redno določati koncentracije kreatinina v serumu:
As metformin is excreted by the kidney, serum creatinine concentrations should be monitored regularly:
Metformin se izloča preko ledvic, zato je treba koncentracije kreatinina v serumu redno spremljati:
As metformin is excreted via the kidney, and elderly patients have a tendency to decreased renal function, elderly patients taking Eucreas should have their renal function monitored regularly (see sections 4.4 and 5.2).
Metformin se izloča preko ledvic, pri starejših bolnikih pa je delovanje ledvic pogosto zmanjšano, zato je treba starejšim bolnikom, ki jemljejo zdravilo Eucreas, redno pregledovati delovanje ledvic (glejte poglavji 4.4 in 5.2).
as monotherapy
amostojno zdravljenje
As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.
Metastatskega raka dojk pri bolnicah s povečanim tveganjem za nastanek bolezni srca, v obliki monoterapije.
as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
kot monoterapija za zdravljenje bolnikov z lokalno napredovalo ali metastatsko obliko raka dojk po neuspešnem zdravljenju s taksani in antraciklinsko kemoterapijo ali za zdravljenje bolnikov, pri katerih nadaljnje zdravljenje z antraciklini ni indicirano.
as monotherapy in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance
kot monoterapija pri odraslih bolnikih (predvsem bolnikih s prekomerno telesno maso) nezadostno nadzorovanih z dieto in gibanjem, pri katerih je metformin, zaradi kontraindikacij ali neprenašanja, neprimeren.
as monotherapy in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.
Kot monoterapija pri odraslih bolnikih (zlasti bolnikih s čezmerno telesno maso), ki imajo bolezen nezadostno urejeno z dieto in telesno dejavnostjo in za katere metformin ni primeren zaradi kontraindikacij ali neprenašanja.
As monotherapy the PegIntron regimen is 0.5 or 1.0 µg/kg/week.
Režim odmerjanja zdravila PegIntron v monoterapiji je 0,5 ali 1,0 g/kg/teden.
As most alkylating agents, thiotepa might impair male or female fertility.
Kot večina alkilirajočih učinkovin lahko tiotepa zmanjša plodnost pri moških in ženskah.
As most events can occur early in the course of treatment, the physician should evaluate the patient closely during the first eight weeks of treatment to determine if dose modifications are warranted.
Ker se lahko večina dogodkov pojavi zgodaj v teku zdravljenja, mora zdravnik bolnika v prvih osmih tednih zdravljenja skrbno spremljati, da oceni, ali je treba odmerek prilagoditi.
As needed.
po potrebi
As no adjustment is necessary, the recommended dose is 0.20 mg/kg/day.
Prilagoditev odmerka ni potrebna, zato je priporočen odmerek 0,20 mg/kg/dan.
As no clinical data are available, dosage recommendations cannot be given for patients with severe hepatic insufficiency (see section 4.2)..
Ker za bolnike s težko insuficienco jeter klinični podatki niso na voljo, za to skupino bolnikov ne moremo dati priporočil o odmerjanju. (glejte poglavje 4.2).
As no clinical data are available, dose recommendations cannot be given for patients with severe hepatic insufficiency (see section 4.2).
Ker za bolnike s težko insuficienco jeter klinični podatki niso na voljo, za to skupino bolnikov ne moremo dati priporočil o odmerjanju. (glejte poglavje 4.2).
As no clinical data are available, dose recommendations cannot be given for patients with severe hepatic insufficiency(see section 4.2). .
Ker za bolnike s težko insuficienco jeter klinični podatki niso na voljo, za to skupino bolnikov ne moremo dati priporočil o odmerjanju. (glejte poglavje 4.2).
As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure.
Ker kliničnih podatkov o izpostavljenosti klopidogrelu med nosečnostjo ni, je kot previdnostni ukrep zaželeno, da se klopidogrela v nosečnosti ne uporabljate.
As noted in Table 4, although the primary endpoint was not met, exploratory analyses show that clinically meaningful results were observed.
Primarni opazovani dogodek sicer ni bil dosežen, vendar pa eksplorativne analize kažejo klinično pomembne rezultate, kot je razvidno iz tabele 4.
As NovoThirteen contains a recombinant protein it may cause allergic reactions including anaphylactic reactions.
Zdravilo NovoThirteen vsebuje rekombinantno beljakovino, zato lahko povzroči alergijske reakcije, vključno z anafilaktičnimi reakcijami.
As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non- blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population (see section 5.1).
Kot so že opazili pri zaviralcih ACE, so irbesartan in drugi antagonisti angiotenzina izrazito manj učinkoviti pri zniževanju krvnega tlaka pri temnopoltih ljudeh kot pri drugih ne-temnopoltih, verjetno zaradi večje prevalence stanj z nizko vrednostjo renina pri temnopoltih bolnikih z visokim krvnim tlakom (glejte poglavje 5.1).
As observed for angiotensin converting enzyme inhibitors, telmisartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population.
Kot kaže, tudi telmisartan in drugi antagonisti angiotenzina – tako kot zaviralci angiotenzinske konvertaze – manj učinkovito znižajo krvni tlak pri črncih kot nečrncih, verjetno zaradi večje prevalence nizkoreninskih stanj pri črni hipertenzivni populaciji.
As observed in euglycemic clamp studies in patients with type 1 diabetes, the glucose lowering effect of Toujeo was more stable and prolonged in comparison with insulin glargine 100 units/ml after subcutaneous injection.
Evglikemične clamp študije pri bolnikih s sladkorno boleznijo tipa 1 so pokazale, da je po subkutanem injiciranju vpliv zdravila Toujeo na znižanje glukoze v krvi stabilnejši in dolgotrajnejši kot z insulinom glarginom 100 enot/ml.
As of the data cutoff date of the interim analysis, 75 (16.2%) subjects in the Kd arm and 88 (18.9%) subjects in the Vd arm had died, corresponding to 33% of total 496 events required for the final analysis (HR = 0.786, 95% CI: 0.575, 1.075) (see figure 4).
Od datuma zamejitve podatkov za vmesno analizo je umrlo 75 (16,2 %) bolnikov v skupini Kd in 88 (18,9 %) bolnikov v skupini Vd, kar ustreza 33 % od skupno 496 dogodkov, potrebnih za končno analizo (HR = 0,786, 95 % IZ: 0,575, 1,075) (glejte sliko 4).
As only limited data available the clinical significance is unknown.
Zaradi maloštevilnih podatkov klinična pomembnost ni znana.
As otitis media is caused by many organisms other than pneumococcal serotypes represented in the vaccine, protection against all otitis media is expected to be low (see section 5.1).
Ker vnetje srednjega ušesa povzročajo poleg pnevmokoknih serotipov, zastopanih v cepivu, še številni drugi mikroorganizmi, pričakujemo, da bo zaščita pred vnetjem srednjega ušesa glede na vse povzročitelje majhna (glejte poglavje 5.1).
As otitis media is caused by many organisms other than pneumococcal serotypes represented in the vaccine, protection against all otitis media is expected to be low.
Ker vnetje srednjega ušesa poleg pnevmokoknih serotipov, zastopanih v cepivu, povzročajo še številni drugi mikroorganizmi, pričakujemo, da bo zaščita pred vnetjem srednjega ušesa glede na vse povzročitelje majhna.
As paliperidone has not been studied in patients with severe hepatic impairment, caution is recommended in such patients.
Ker paliperidona niso preučevali pri bolnikih s hudo jetrno okvaro, je pri njih potrebna previdnost.
As paliperidone has not been studied in patients with severe hepatic impairment, caution is recommended in such patients. (See section 5.2).
Ker paliperidona niso preučevali pri bolnikih s hudo okvaro jeter, je pri njih potrebna previdnost (glejte poglavje 5.2).
As palonosetron may increase large bowel transit time, patients with a history of constipation or signs of subacute intestinal obstruction should be monitored following administration.
Ker lahko palonosetron podaljša čas prehoda skozi debelo črevo, je treba bolnike z anamnezo zaprtja ali znaki subakutne zapore črevesa po dajanju zdravila spremljati.
As part of the Erivedge Pregnancy Prevention Programme, all patients will receive a:
V okviru Programa preprečevanja nosečnosti med uporabo zdravila Erivedge bodo vsi bolniki prejeli:
As part of the monitoring of the patient’s psoriasis, physicians should be alert for symptoms of erythrodermic psoriasis or exfoliative dermatitis.
Med spremljanjem bolnika s psoriazo mora biti zdravnik pozoren na simptome eritrodermične psoriaze ali eksfoliativnega dermatitisa.
As part of the pivotal trial with ReFacto in PUPs, ITI data from 25 patients were reviewed (see Section 4.8).
V sklopu ključnega preskušanja zdravila ReFacto pri PUP so ocenili podatke o ITI pri 25 bolnikih (glejte poglavje 4.8).
as part of treatment strategies for flea allergy dermatitis (an allergic reaction to flea bites) in cats and dogs
kot del strategije zdravljenja alergijskega dermatitisa, ki ga povzročajo bolhe (alergijske reakcije na ugrize bolh) pri mačkah in psih;
As part of your treatment you may be given other medicines.
Kot del zdravljenja morda dobivate še druga zdravila.
As patient’s genetic disposition may be unknown, it is recommended that patients be monitored for impaired mental or physical abilities needed to perform potentially hazardous activities such as driving a car or using machines (see sections 4.7. and 4.8).
Ker bolnikova genska nagnjenost morda ni znana, se priporoča spremljanje bolnikov zaradi morebitnega poslabšanja duševnih ali telesnih sposobnosti, ki so potrebne za opravljanje potencialno nevarnih dejavnosti, kot sta vožnja avtomobila ali upravljanje strojev (glejte poglavji 4.7 in 4.8).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, any updated RMP should be submitted at the same time as the following Periodic Safety Update Report (PSUR).
V skladu s smernicami CHMP za sisteme za obvladovanje tveganja za zdravila za uporabo v humani medicini mora biti posodobljen RMP predložen hkrati z naslednjim rednim posodobljenim poročilom o varnosti zdravila (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, any updated RMP should be submitted at the same time as the following Periodic Safety Update Report (PSUR).
V skladu s smernico CHMP o sistemih upravljanja s tveganji za zdravila za uporabo v humani medicini je treba posodobljeni RMP predložiti hkrati z naslednjim rednim dopolnjenim poročilom o varnosti zdravila (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR) (i.e. in the pre-pandemic period).
V skladu s smernico CHMP o sistemih za obvladovanje tveganj za zdravila za uporabo v humani medicini je treba posodobljen RMP predložiti hkrati z naslednjim rednim posodobljenim poročilom o varnosti zdravila (PSUR) (tj. v predpandemičnem obdobju).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
Glede na Smernico CHMP o sistemih za upravljanje s tveganji za zdravila v humani medicini, je potrebno posodobljen Načrt za upravljanje s tveganji oddati istočasno kot periodično poročilo o varnosti zdravila (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
V skladu s smernicami CHMP za sisteme za obvladovanje tveganja za zdravila za uporabo v humani medicini je treba posodobljen RMP predložiti hkrati z naslednjim rednim posodobljenim poročilom o varnosti zdravila (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
V skladu s smernico CHMP o sistemih za obvladovanje tveganj za zdravila za uporabo v humani medicini mora biti posodobljen RMP predložen hkrati z naslednjim rednim posodobljenim poročilom o varnosti zdravila (PSUR).
As Perjeta is used with trastuzumab and chemotherapy, it is difficult to ascertain the causal relationship of an adverse event to a particular medicinal product.
Ker se zdravilo Perjeta uporablja skupaj s trastuzumabom in kemoterapijo, je težko ugotoviti vzročno povezanost neželenega učinka s posameznim zdravilom.
As pimobendan is metabolised in the liver, the product should not be administered in dogs with severe hepatic insufficiency.
Ker se pimobendan presnavlja v jetrih, se zdravila ne sme dajati psom s hudo okvaro jeter.
As pramipexole treatment inhibits secretion of prolactin in humans, inhibition of lactation is expected.
Zdravljenje s pramipeksolom zavira izločanje prolaktina pri človeku, zato je zaviranje laktacije pričakovano.
As pre-haemodialysis and haemodialysis patients are particularly exposed to HBV and have a higher risk to become chronically infected, a precautionary attitude should be considered i.e. giving a booster dose in order to ensure a protective antibody level as defined by national recommendations and guidelines.
Ker so predhemodializni in hemodializni bolniki še posebej izpostavljeni okužbi s HBV in ker je pri njih tveganje za kronično okužbo večje, je potrebno razmisliti o previdnostnih ukrepih, npr. cepljenje z obnovitvenim odmerkom, da bi tako zagotovili takšen zaščitni titer protiteles, kot je definiran z nacionalnimi priporočili in smernicami.
As pregabalin clearance is directly proportional to creatinine clearance (see section 5.2), dose reduction in patients with compromised renal function must be individualised according to creatinine clearance (CLcr), as indicated in table 1 determined using the following formula.
Očistek pregabalina je neposredno sorazmeren očistku kreatinina (glejte poglavje 5.2), zato je treba pri bolnikih z okrnjenim delovanjem ledvic odmerek individualno prilagoditi glede na očistek kreatinina (CLcr), kot prikazuje preglednica 1, po naslednji formuli:
As prostaglandins are substances that trigger inflammation, pain, exudation (fluid that leaks out of blood vessels during an inflammation) and fever, meloxicam reduces these signs of disease.
Ker so prostaglandini snovi, ki povzročajo vnetje, bolečino, izcedke tekočine (izcejanje tekočine iz krvnih žil med vnetjem) in povišano telesno temperaturo, meloksikam zmanjšuje znake te bolezni.
As prostaglandins trigger inflammation, pain, exudation (fluid that leaks out of blood vessels during an inflammation) and fever, meloxicam reduces these signs of disease.
Prostaglandini sprožajo vnetje, bolečino in izcejanje tekočine (izcejanje tekočine iz krvnih žil med vnetnim procesom) in povišano telesno temperaturo, meloksikam pa te bolezenske znake zmanjšuje.
As protein binding is low, dabigatran can be dialysed; there is limited clinical experience to demonstrate the utility of this approach in clinical studies (see section 5.2).
Ker se ga na beljakovine veže malo, je dabigatran mogoče dializirati, o čemer pa je malo kliničnih izkušenj, ki bi kazale na tovrstno uporabnost v kliničnih študijah (glejte poglavje 5.2).
As protein binding is low, dabigatran can be dialysed; there is limited clinical experience to demonstrate the utility of this approach in clinical studies (see section 5.2).
Zaradi majhne vezave na beljakovine, je dabigatran mogoče dializirati: vendar je le malo kliničnih izkušenj, ki bi kazale na tovrstno uporabnost v kliničnih študijah (glejte poglavje 5.2).
As recombinant coagulation factor VIIa NovoSeven may contain trace amounts of mouse IgG, bovine IgG and other residual culture proteins (hamster and bovine serum proteins), the remote possibility exists that patients treated with the product may develop hypersensitivity to these proteins.
Rekombinantni koagulacijski faktor VIIa zdravila NovoSeven lahko vsebuje sledi mišjih IgG, govejih IgG in drugih rezidualnih beljakovin kulture (hrčkove in goveje serumske beljakovine), zato obstaja pri bolnikih, ki dobivajo to zdravilo, neznatna možnost za pojav preobčutljivosti na te beljakovine.
As recommended for other biological treatments, RA, patients should be screened for latent tuberculosis (TB) infection prior to starting RoActemra therapy.
Kot velja za druga biološka zdravila, je treba bolnike z revmatoidnim artritisom pred začetkom zdravljenja z zdravilom RoActemra presejalno pregledati glede latentne tuberkuloze.
As Recuvyra contains fentanyl (the active substance), it will only ever be kept in a veterinarian’s surgery under secure conditions.
Ker Recuvyra vsebuje fentanil (zdravilno učinkovino), se shranjuje samo v veterinarskem kirurškem oddelku v varnih pogojih.
As regards other P-gp substrates such as dabigatran, clinical monitoring is recommended in case of combination with vandetanib.
Kar zadeva druge substrate P-gp kot je dabigatran, je priporočljivo klinično spremljanje v primeru uporabe skupaj z vandetanibom.
As renal excretion is a main pathway of elimination, dose reduction of Siklos should be considered in patients with renal impairment.
Ker je ledvično izločanje glavna pot eliminacije, je treba pri bolnikih z ledvično okvaro razmisliti o zmanjšanju odmerka zdravila Siklos.
As renal function decreases with age this is the only factor to take into consideration (see renal impairment section).
Ker se delovanje ledvic z leti zmanjšuje, je to edini dejavnik, ki ga je treba upoštevati (glejte razdelek o okvari ledvic).
As renal function generally decreases with age, elderly patients may show reduced elimination and increased exposure of fondaparinux (see section 5.2).
Ledvična funkcija s starostjo na splošno upada, zato je lahko pri starejših bolnikih zmanjšano izločanje in povečana izpostavljenost fondaparinuksu (glejte poglavje 5.2).
As renal impairment may be frequent in the elderly (>75 years), renal function should be assessed by calculating the CrCL prior to initiation of treatment with Pradaxa to exclude patients with severe renal impairment (i.e.
Ker je ledvična okvara pri starejših (> 75 let) pogosta, je treba pred začetkom zdravljenja z zdravilom Pradaxa na podlagi izračuna CrCl oceniti delovanje njihovih ledvic, da bi lahko izključili bolnike s hudo ledvično okvaro (tj.
As reported in a recent publication 21 of these 65patients also achieved complete molecular remission with a median follow-up of 28months (range 13-67months).
Kot so nedavno objavili, je 21 od teh 65 bolnikov doseglo tudi popolno molekularno remisijo po mediano
As reported with Haemophilus b Polysaccharide Vaccine and another Haemophilus b Conjugate Vaccine, cases of Haemophilus b disease may occur in the week after vaccination, prior to the onset of the protective effects of the vaccines.
Kot je opisano pri polisaharidnem cepivu proti hemofilusu b in drugem konjugiranem cepivu proti hemofilusu b, se lahko v tednu po cepljenju, to je še pred nastopom zaščitnega učinka cepiv, pojavijo primeri bolezni zaradi hemofilusa b.
As Ristfor contains metformin hydrochloride, the treatment should be discontinued 48 hours before elective surgery with general, spinal or epidural anaesthesia.
Zdravilo Ristfor vsebuje metforminijev klorid, zato je treba zdravljenje prekiniti 48 ur pred elektivno operacijo pod splošno, spinalno ali epiduralno anestezijo.
As ritonavir is recommended to be taken with food and didanosine should be taken on an empty stomach, dosing should be separated by 2.5 h.
Zato mora med uporabo enega in drugega miniti 2,5 ure.
As rivastigmine has a plasma half-life of about 1 hour and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose no further dose of rivastigmine should be administered for the next 24 hours.
Ker ima rivastigmin plazemski razpolovni čas okrog 1 ure in trajanje zaviranja acetilholinesteraze okrog 9 ur, priporočamo, da v primeru asimptomatičnega prevelikega odmerka bolnik v naslednjih 24 urah ne prejme nadaljnjih odmerkov rivastigmina.
As rivastigmine has a plasma half-life of about 1 hour and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose no further dose of rivastigmine should be administered for the next 24 hours.
Razpolovni čas rivastigmina v plazmi je približno 1 ura, trajanje zaviranja acetilholinesteraze pa približno 9 ur, zato je pri asimptomatičnem prevelikem odmerjanju priporočljivo naslednjih 24 ur prekiniti dajanje dodatnih odmerkov rivastigmina.
As rivastigmine has a plasma half-life of about 3.4 hours and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose all Rivastigmine 3M Health Care Ltd. transdermal patches should be removed immediately and no further transdermal patch should be applied for the next 24 hours.
Ker ima rivastigmin plazemski razpolovni čas okrog 3,4 ure in trajanje zaviranja acetilholinesteraze okrog 9 ur, v primeru asimptomatičnega prevelikega odmerka priporočamo takojšnjo odstranitev vseh transdermalnih obližev Rivastigmin 3M Health Care Ltd..
As Ryzodeg contains a rapid-acting meal-time insulin (insulin aspart), prandial glycaemic control at the dosing meal is improved relative to administering basal insulin only; see trial results in Table 1.
Ker zdravilo Ryzodeg vsebuje tudi hitrodelujoči insulin, ki se uporablja med obroki (insulin aspart), je bila prandialna urejenost glikemije med obrokom, ko so si aplicirali insulin, boljša z zdravilom Ryzodeg v primerjavi z bazalnim insulinom; glejte rezultate preskušanj v preglednici 1.
As safety and efficacy of repetition of the treatment to treat fibrosarcoma recurrence have not been investigated, repetition of the treatment should be considered by the veterinarian taking into account the benefit-risk balance.
Ker varnost in učinkovitost ponovnega zdravljenja za preprečevanje ponovitve bolezni fibrosarkoma ni bilo raziskano, mora o ponovnem zdravljenju odločati veterinar na osnovi ocene razmerja med koristjo in tveganjem.
As seen in Table 2, in the NB-301 study subjects had a mean percent body weight loss of -5.4% while receiving naltrexone / bupropion compared to -1.3% in placebo-treated subjects.
Kot je prikazano v Preglednici 2, so preiskovanci v študiji NB-301 zabeležili povprečno odstotno zmanjšanje telesne mase v vrednosti -5,4 % pri uporabi naltreksona/bupropiona v primerjavi z vrednostjo -1,3 % pri preiskovancih, ki so prejemali placebo.
As serious and life threatening hepatotoxicity has been observed in controlled and uncontrolled studies predominantly in patients with a plasma HIV-1 viral load of 50 copies/ml or higher, nevirapine should not be initiated in adult females with CD4 cell counts greater than 250 cells/mm3 or in adult males with CD4 cell counts greater than 400 cells/mm3, who have a detectable plasma HIV-1 RNA unless the benefit outweighs the risk.
Ker so v nadzorovanih in nenadzorovanih raziskavah poročali o resni in življenjsko nevarni hepatotoksičnosti pretežno pri bolnikih z virusnim bremenom s HIV-1 50 kopiij/ml ali večjim, ne smemo uvesti nevirapin pri odraslih ženskah s številom celic CD4 nad 250 celic/mm3 in odraslih moških s številom celic CD4 nad 400 celic mm3, in izmerljivo ravnijo HIV-1 RNA v plazmi razen, če je korist zdravljenja večja od njegovega tveganja.